The Antenatal Corticosteroids Trial (ACT): a secondary analysis to explore site differences in a multi-country trial

Karen Klein, Elizabeth M McClure, Daniela Colaci, Vanessa Thorsten, Patricia L Hibberd, Fabian Esamai, Ana Garces, Archana Patel, Sarah Saleem, Omrana Pasha, Elwyn Chomba, Waldemar A Carlo, Nancy F Krebs, Shivaprasad Goudar, Richard J Derman, Edward A Liechty, Marion Koso-Thomas, Pierre M Buekens, José M Belizán, Robert L Goldenberg, Fernando Althabe, Karen Klein, Elizabeth M McClure, Daniela Colaci, Vanessa Thorsten, Patricia L Hibberd, Fabian Esamai, Ana Garces, Archana Patel, Sarah Saleem, Omrana Pasha, Elwyn Chomba, Waldemar A Carlo, Nancy F Krebs, Shivaprasad Goudar, Richard J Derman, Edward A Liechty, Marion Koso-Thomas, Pierre M Buekens, José M Belizán, Robert L Goldenberg, Fernando Althabe

Abstract

Background: The Antenatal Corticosteroid Trial (ACT) assessed the feasibility, effectiveness, and safety of a multifaceted intervention to increase the use of antenatal corticosteroids (ACS) in mothers at risk of preterm birth at all levels of care in low and middle-income countries. The intervention effectively increased the use of ACS but had no overall impact on neonatal mortality in the targeted <5(th) percentile birth weight infants. Being in the intervention clusters was also associated with an overall increase in neonatal deaths. We sought to explore plausible pathways through which this intervention increased neonatal mortality.

Methods: We conducted secondary analyses to assess site differences in outcome and potential explanations for the differences in outcomes if found. By site, and in the intervention and control clusters, we evaluated characteristics of the mothers and care systems, the proportion of the <5(th) percentile infants and the overall population that received ACS, the rates of possible severe bacterial infection (pSBI), determined from clinical signs, and neonatal mortality rates.

Results: There were substantial differences between the sites in both participant and health system characteristics, with Guatemala and Argentina generally having the highest levels of care. In some sites there were substantial differences in the health system characteristics between the intervention and control clusters. The increase in ACS in the intervention clusters was similar among the sites. While overall, there was no difference in neonatal mortality among <5(th) percentile births between the intervention and control clusters, Guatemala and Pakistan both had significant reductions in neonatal mortality in the <5(th) percentile infants in the intervention clusters. The improvement in neonatal mortality in the Guatemalan site in the <5(th) percentile infants was associated with a higher level of care at the site and an improvement in care in the intervention clusters. There was a significant increase overall in neonatal mortality in the intervention clusters compared to the control. Across sites, this increase in neonatal mortality was statistically significant and most apparent in the African sites. This increase in neonatal mortality was accompanied by a significant increase in pSBI in the African sites.

Conclusions: The improvement in neonatal mortality in the Guatemalan site in the <5(th) percentile infants was associated with a higher level of care and an improvement in care in the intervention clusters. The increase in neonatal mortality in the intervention clusters across all sites was largely driven by the poorer outcomes in the African sites, which also had an increase in pSBI in the intervention clusters. We emphasize that these results come from secondary analyses. Additional prospective studies are needed to assess the effectiveness and safety of ACS on neonatal health in low resource settings.

Trial registration: clinicaltrials.gov (NCT01084096).

Figures

Fig. 1
Fig. 1
The RR of 28-day neonatal mortality among

Fig. 2

The RR of 28-day neonatal…

Fig. 2

The RR of 28-day neonatal mortality comparing the intervention to control clusters among…

Fig. 2
The RR of 28-day neonatal mortality comparing the intervention to control clusters among all births by site

Fig. 3

RR of pSBI comparing the…

Fig. 3

RR of pSBI comparing the intervention to control clusters among all births by…

Fig. 3
RR of pSBI comparing the intervention to control clusters among all births by site (adjusted for pretrial pSBI rates)
Fig. 2
Fig. 2
The RR of 28-day neonatal mortality comparing the intervention to control clusters among all births by site
Fig. 3
Fig. 3
RR of pSBI comparing the intervention to control clusters among all births by site (adjusted for pretrial pSBI rates)

References

    1. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454.
    1. McLaughlin KJ, Crowther CA, Walker N, Harding JE. Effects of a single course of corticosteroids given more than 7 days before birth: a systematic review. Aust N Z J Obstet Gynaecol. 2003;43(2):101–6. doi: 10.1046/j.0004-8666.2003.00052.x.
    1. Darmstadt G, Bhutta Z, Cousens S, Adam T, Walker N, de Bernis L. Evidence-based, cost-effective interventions: how many newborn babies can we save? Lancet. 2005;365:977–88. doi: 10.1016/S0140-6736(05)71088-6.
    1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515–25.
    1. Ballard PL, Gluckman PD, Liggins GC, Kaplan SL, Grumbach MM. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. Pediatr Res. 1980;14(2):122–7. doi: 10.1203/00006450-198002000-00011.
    1. Braun T, Sloboda DM, Tutschek B, Harder T, Challis JR, Dudenhausen JW, Plagemann A, Henrich W. Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration. Int J Gynaecol Obstet. 2015;130(1):64–9. doi: 10.1016/j.ijgo.2015.01.013.
    1. Bhutta Z, Das J, Bahl R, The Lancet Newborn Interventions Review Group and The Lancet Every Newborn Study Group Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost? Lancet. 2014;384:347–70. doi: 10.1016/S0140-6736(14)60792-3.
    1. Lawn J, Blencowe H, Oza S, The Lancet Every Newborn Study Group Every Newborn: progress, priorities, and potential beyond survival. Lancet. 2014;384:189–205. doi: 10.1016/S0140-6736(14)60496-7.
    1. Katz J, Lee A, Kozuki N, and the CHERG Small-for-Gestational-Age-Preterm Birth Working Group Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. Lancet. 2013;382:417–25. doi: 10.1016/S0140-6736(13)60993-9.
    1. Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn J. Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth. Int J Epidemiol. 2010;39(suppl 1):122–33. doi: 10.1093/ije/dyq029.
    1. Vargas-Origel A, Leon Ramirez D, Zamora-Orozco J. Corticoesterides antenatales: empleo y actitud del personal medico ginecoobstetra. Ginecol Obstet Mex. 2000;68:291–95.
    1. Short J, McDonald S, Turner T, Martis R, SEA-ORCHID Study Group Improving capacity for evidence-based practice in South East Asia: evaluating the role of research fellowships in the SEA-ORCHID Project. BMC Med Educ. 2010;10:37. doi: 10.1186/1472-6920-10-37.
    1. Althabe F, Belizán JM, Mazzoni A, et al. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries: study protocol. Reprod Health. 2012;9:22. doi: 10.1186/1742-4755-9-22.
    1. Althabe F, Belizán JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015;385(9968):629–39. doi: 10.1016/S0140-6736(14)61651-2.
    1. Bose CL, Bauserman M, Goldenberg RL, Goudar SS, McClure EM, Pasha O, Carlo WA, Garces A, Moore JL, Miodovnik M, Koso-Thomas M. The Global Network Maternal Newborn Health Registry: a multi-national, community-based registry of pregnancy outcomes. Reprod Health. 2015;12(Suppl 2):S1. doi: 10.1186/1742-4755-12-S2-S1.
    1. Goudar SS, Carlo WA, McClure EM, et al. The Maternal and Newborn Health Registry study of the Global Network for Women’s and Children’s Health Research. Int J Gynecol Obstet. 2012;118:190–93. doi: 10.1016/j.ijgo.2012.04.022.
    1. Young infants clinical signs study group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet. 2008;371(9607):135–42.
    1. Seale AC, Blencowe H, Manu AA, Nair H, Bahl R, Qazi SA, et al. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and metaanalysis. Lancet Infect Dis. 2014;14(8):731–41.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi